Collected data from the Anxiety and Depression Association of America (ADAA) suggests that upwards of 40 million adults are affected by anxiety, or approximately 18% of the United States population. Among the 40 million adults who are affected by anxiety, it is estimated that approximately: 19 million suffer from specific phobias; 15 million suffer from …
Research suggests that upwards of 16 million American adults (6.7% of the adult population) are afflicted with major depressive disorder (MDD), a neuropsychiatric condition characterized by overwhelming sadness, behavioral changes, sleep disturbances, and cognitive deficits. As of current, depression is the leading cause of disability in the United States among individuals between the ages of …
CBD (Cannabidiol) is a phytocannabinoid with medicinal properties derived from the cannabis plant (i.e. marijuana). Of all ~113 active phytocannabinoids, or plant-based chemical constituents within the cannabis plant, cannabidiol is most abundant and accounts for approximately 40% of the plant’s extract. Unlike other phytocannabinoids that induce intoxicating effects (e.g. THC or tetrahydrocannabinol), cannabidiol is devoid …
Zoloft (Sertraline), is an SSRI (selective serotonin reuptake inhibitor) prescribed for the treatment of major depressive disorder, OCD (obsessive-compulsive disorder), panic disorder, and social anxiety disorder. It was approved by the FDA in 1991 and initially marketed by the pharmaceutical company Pfizer. In 2013, Zoloft became the single most popular antidepressant medication in the United …
Humira (Adalimumab) is a biologic, immunosuppressant medication sold and marketed by the pharmaceutical company AbbVie Inc. More specifically, Humira functions as a TNF inhibitor whereby it binds to and blocks the physiologic effect of the proinflammatory cytokine known as “TNF-alpha.” Blockade of inflammation induced by TNF-alpha makes Humira useful for the treatment of many autoimmune …
Rexulti (Brexpiprazole), is an atypical antipsychotic that was jointly developed by pharmaceutical companies Otsuka and Lundbeck. In 2015, the FDA approved Rexulti for the treatment of schizophrenia and major depressive disorder (as an adjunct). Rexulti functions as a “serotonin-dopamine activity modulator” (SDAM) and is intended to be a superior successor to the antipsychotic Abilify (Aripiprazole) …
Trintellix (Vortioxetine hydrobromide), formerly sold under the name Brintellix, is an antidepressant that was jointly developed by the pharmaceutical companies Lundbeck and Takeda. In 2013, Trintellix received FDA approval for the treatment of major depressive disorder in the United States. Trintellix is classified as a “serotonin modulator and stimulator” in that it functions as an …